Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth

Journal of the National Cancer Institute

Volumn 90, Issue 20, 1998, Pages 1552-1558

  O'Regan, Ruth M ^a   Cisneros, Angela ^b   England, Gale M ^b   MacGregor, Jennifer I ^b   Muenzner, Henry D ^b   Assikis, Vasilios J ^b   Bilimoria, Malcolm M ^b   Piette, Michael ^b   Dragan, Yvonne P ^c   Pitot, Henry C ^c   Chatterton, Robert ^b   Jordan, V Craig ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN; FULVESTRANT; TAMOXIFEN; TOREMIFENE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032556191     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.20.1552     Document Type: Article

References (38)

1. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812-5.
2. Horwitz RI, Feinstein AR, Horwitz SM, Robboy SJ. Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies. Lancet 1981; 2:66-8.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 62 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-92.
4. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
5. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A: 1464-76.
6. Barakat RR. Endometrial cancer and tamoxifen. In: Jordan VC, editor. Tamoxifen: a guide for clinicians and patients. Huntington (NY): PRR; 1996. p. 101-7.
7. International Agency for Research on Cancer (IARC): Tamoxifen. IARC Monographs 1996;66:274-365 (http://www.iarc.fr/preleases/111e.htm).
8. Valavaara R, Pyrhonen S, Heikkinen M, Rissanen P, Blanco G, Tholix E, et al. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 1988;24: 785-90.
9. Gundersen S. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study. J Steroid Biochem 1990; 36:233-4.
10. Modig H, Borgstrom M, Nilsson I, Westman G. Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication. J Steroid Biochem 1990;36:235-6.
11. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995;13:2556-66.
12. Wakeling AE, Bowler J. ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 1992;43:173-7.
13. Howell A, Defriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996;74:300-8.
14. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993;53:4534-41.
15. Hirsimaki P, Hirsimaki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol 1993;67:49-54.
16. Clarke CL, Satyaswaroop PG. Photoaffinity labeling of the progesterone receptor from human endometrial carcinoma. Cancer Res 1985;45: 5417-20.
17. Robinson SP, Jordan VC. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 1989;49:1758-62.
18. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 1991;19: 36-43.
19. Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR, et al. Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995;55:1070-4.
20. Fried KM, Wainer IW. Direct determination of tamoxifen and its four metabolites in plasma using coupled column high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994;655:261-8.
21. Peluso JJ. Structure and function of the mammalian ovary. In: Gass GH, Kaplan HM, editors. Handbook of endocrinology. 2nd ed. Boca Raton (FL): CRC Press; 1996. p. 101-19.
22. Odell WD. The menopause. In: DeGroot LJ, editor. Endocrinology. 2nd ed. Philadelphia: WB Saunders Co.; 1989. p. 2009-18.
23. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 1993;11:345-50.
24. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992;11:117-20.
25. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial. J Natl Cancer Inst Monogr 1992;11:121-5.
26. Pyrhonen S, Valavaara R, Vuorinen J, Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 1994;29:223-8.
27. di Salle E, Zaccheo T, Ornati G. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 1990;36:203-6.
28. Han XL, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992;52:1360-3.
29. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993;14:315-7.
30. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993;53:3919-24.
31. Phillips DH, Carmichael PL, Hewer A, Cole KJ, Hardcastle IR, Poon GK, et al. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 1996;17:89-94.
32. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995;16:1651-4.
33. Carmichael PL, Ugwumadu AH, Neven P, Hewer AJ, Poon GK, Phillips DH. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996;56:1475-9.
34. Hemminki K, Rajaniemi H, Lindahl B, Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 1996;56:4374-7.
35. Dal Cin P, Timmerman D, Van den Berghe I, Wanschura S, Kazmierczak B, Vergote I, et al. Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Res 1998;58:2278-81.
36. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995;59: 261-6.
37. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
38. Dukes M, Miller D, Wakeling AE, Waterton JC. Antiuterotrophic effects of a pure antioestrogen. ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 1992;135: 239-47.